DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and ten approved drugs.

There are sixty-seven US patents protecting TEVA drugs. There are forty-three tentative approvals on TEVA drugs.

There are seven hundred and eighty-nine patent family members on TEVA drugs in forty-six countries and five hundred and thirty-five supplementary protection certificates in fourteen countries.

Summary for Teva

International Patents:	789
US Patents:	67
Tradenames:	469
Ingredients:	412
NDAs:	710

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	CEFPROZIL	cefprozil	FOR SUSPENSION;ORAL	065236-002	Dec 8, 2005	AB	RX	No	No
Teva	DONEPEZIL HYDROCHLORIDE	donepezil hydrochloride	TABLET;ORAL	077344-002	May 31, 2011	AB	RX	No	No
Teva Branded Pharm	PROAIR RESPICLICK	albuterol sulfate	POWDER, METERED;INHALATION	205636-001	Mar 31, 2015		RX	Yes	Yes
Teva Pharms Usa	DESMOPRESSIN ACETATE	desmopressin acetate	INJECTABLE;INJECTION	074888-001	Oct 15, 1997		DISCN	No	No

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000	5,605,674
Teva Branded Pharm	SEASONALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021544-001	Sep 5, 2003	RE39861
Teva	AZILECT	rasagiline mesylate	TABLET;ORAL	021641-001	May 16, 2006	5,457,133

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1.25 mg		2008-11-03
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Tablets	0.5 mg and 1 mg		2010-05-17
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Delayed-release Tablets	20 mg		2015-06-03
	Tablets	0.625 mg		2009-03-02
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.3 mg, 0.45 mg and 0.9 mg		2009-03-19
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	for Injection	3.5 mg/vial		2016-10-26

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

Non-Orange Book US Patents for Teva

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,179,799	(3) and (6) substituted estrogenic compounds
7,459,445	Estrogenic compounds and topical pharmaceutical formulations of the same
8,877,245	Modified release dosage forms of skeletal muscle relaxants
7,749,989	Estrogenic compounds, methods of using and methods of administering the same

International Patents for Teva Drugs

Country	Document Number	Estimated Expiration
Australia	2007238685
Eurasian Patent Organization	201390745
Cyprus	1116148
China	105770855

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
00085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
C0008	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107
14/032	Ireland		PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
16/1996	Austria		PRODUCT NAME: LOSARTAN-KALIUM

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm